[AFFINOLEUKINE IS AN IMMUNOTHERAPEUTIC ADJUVANT IN THE TREATMENT OF PULMONARY TUBERCULOSIS IN ADOLESCENTS].
The clinical and immunological efficacy of the immunotherapeutic drug affinoleukine (AFL) in the treatment of pulmonary tuberculosis was studied in adolescents. Examination of patients who had mainly infiltrative pulmonary tuberculosis in the randomized study and control groups (23 subjects in each group) showed the good clinical tolerability of the drug and the signs of more effective resolution of infiltrative changes in the study group. An immunological study of the patients receiving AFL ascertained the higher specific antigen-induced production of interferon-γ (IFN-γ) in the whole blood samples in vitro; immunophenotyping showed a higher percentage of circulating gamma/delta T lymphocytes and a lower proportion of a subpopulation of IFN-γ-producing gamma/delta T lymphocytes, including in vitro antigen-induced ones. It is assumed that AFL increases the migration of effector gamma/delta cells to the foci of tuberculous inflammation.